Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Rating) major shareholder Tpg Gp A, Llc sold 436,431 shares of the stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $2.86, for a total value of $1,248,192.66. Following the transaction, the insider now owns 3,888,452 shares in the company, valued at $11,120,972.72. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
特雷维治疗公司(纳斯达克代码：TRVI-GET评级)的大股东TPG GP A，LLC在7月1日星期五的一笔交易中出售了436,431股该股票。这只股票的平均售价为2.86美元，总价值为1248,192.66美元。交易完成后，这位内部人士现在拥有该公司3888,452股，价值11,120,972.72美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，通过这个链接可以访问该文件。持有公司至少10%股份的大股东必须披露他们与美国证券交易委员会的交易。
Tpg Gp A, Llc also recently made the following trade(s):
TPG GP A，LLC最近还进行了以下交易：
- On Tuesday, July 5th, Tpg Gp A, Llc sold 63,569 shares of Trevi Therapeutics stock. The stock was sold at an average price of $3.11, for a total value of $197,699.59.
- On Wednesday, June 29th, Tpg Gp A, Llc sold 46,128 shares of Trevi Therapeutics stock. The stock was sold at an average price of $2.74, for a total value of $126,390.72.
- On Monday, May 2nd, Tpg Gp A, Llc sold 600 shares of Trevi Therapeutics stock. The stock was sold at an average price of $2.70, for a total value of $1,620.00.
- On Thursday, April 28th, Tpg Gp A, Llc sold 7,271 shares of Trevi Therapeutics stock. The stock was sold at an average price of $2.77, for a total value of $20,140.67.
- 7月5日，星期二，TPG GP A，LLC出售了63,569股Trevi治疗公司的股票。这只股票的平均售价为3.11美元，总价值为197699.59美元。
- 6月29日，星期三，TPG GP A，LLC出售了46,128股Trevi Treeutics股票。这只股票的平均售价为2.74美元，总价值为126,390.72美元。
- 5月2日，星期一，TPG GP A，LLC出售了600股Trevi治疗公司的股票。这只股票的平均售价为2.70美元，总价值为1,620.00美元。
- 4月28日，星期四，TPG GP A，LLC出售了7271股Trevi治疗公司的股票。这只股票的平均售价为2.77美元，总价值为20,140.67美元。
NASDAQ TRVI opened at $3.79 on Friday. The firm has a market capitalization of $146.64 million, a P/E ratio of -2.81 and a beta of 0.18. The business has a fifty day simple moving average of $2.40 and a 200 day simple moving average of $1.74. Trevi Therapeutics, Inc. has a 12 month low of $0.46 and a 12 month high of $3.86. The company has a current ratio of 2.32, a quick ratio of 2.32 and a debt-to-equity ratio of 0.67.
Institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Trevi Therapeutics by 7.6% during the 1st quarter. Vanguard Group Inc. now owns 152,831 shares of the company's stock valued at $336,000 after purchasing an additional 10,780 shares during the last quarter. State Street Corp purchased a new stake in shares of Trevi Therapeutics during the 1st quarter valued at $81,000. Virtu Financial LLC purchased a new stake in shares of Trevi Therapeutics during the 1st quarter valued at $44,000. Commonwealth Equity Services LLC purchased a new stake in shares of Trevi Therapeutics during the 1st quarter valued at $33,000. Finally, MAI Capital Management purchased a new stake in shares of Trevi Therapeutics during the 1st quarter valued at $3,391,000. 75.34% of the stock is owned by hedge funds and other institutional investors.
机构投资者最近对他们在该公司的头寸进行了调整。先锋集团第一季度增持Trevi治疗公司股票7.6%。先锋集团目前持有152,831股该公司股票，价值33.6万美元，该公司在上个季度又购买了10,780股。道富银行在第一季度购买了Trevi治疗公司的新股份，价值81,000美元。Virtu Financial LLC在第一季度购买了Trevi治疗公司的新股份，价值4.4万美元。英联邦股权服务有限责任公司在第一季度购买了Trevi治疗公司的新股份，价值3.3万美元。最后，Mai资本管理公司在第一季度购买了Trevi治疗公司的新股份，价值3391,000美元。75.34%的股票由对冲基金和其他机构投资者持有。
A number of equities analysts recently issued reports on the company. Oppenheimer increased their target price on Trevi Therapeutics to $12.00 in a report on Monday. Needham & Company LLC increased their target price on Trevi Therapeutics from $8.00 to $10.00 and gave the stock a "buy" rating in a report on Wednesday, June 29th. Finally, Aegis assumed coverage on Trevi Therapeutics in a research report on Tuesday, March 29th. They issued a "buy" rating and a $10.00 price target for the company.
一些股票分析师最近发布了关于该公司的报告。奥本海默在周一的一份报告中将他们对Trevi治疗公司的目标价上调至12.00美元。Needham&Company LLC在6月29日(星期三)的一份报告中将Trevi Treeutics的目标价从8.00美元上调至10.00美元，并给予该股“买入”评级。最后，宙斯盾在3月29日星期二的一份研究报告中对Trevi治疗公司进行了报道。他们对该公司的评级为“买入”，目标价为10.00美元。
About Trevi Therapeutics (Get Rating)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis.
- Get a free copy of the StockNews.com research report on Trevi Therapeutics (TRVI)
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Credo Technology Stock is Rebounding
- Investing In Preferred Stock vs. Common Stock
- Profiting From 52 Week Low Stocks
- Three Cheap Stocks The Insiders Are Buying
Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.